Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Akiyama Y, Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Araki K, Ichikawa W, Miya T, Narabayashi M, Kawara K, Sugiyama M, Hirose T, Ando Y, Sasaki Y. Akiyama Y, et al. Among authors: kawara k. Ann Oncol. 2008 Dec;19(12):2089-90. doi: 10.1093/annonc/mdn645. Epub 2008 Oct 26. Ann Oncol. 2008. PMID: 18953066 Free PMC article. No abstract available.
Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Ichikawa W, Araki K, Fujita K, Yamamoto W, Endo H, Nagashima F, Tanaka R, Miya T, Kodama K, Sunakawa Y, Narabayashi M, Ando Y, Akiyama Y, Kawara K, Sasaki Y. Ichikawa W, et al. Among authors: kawara k. J Natl Cancer Inst. 2008 Feb 6;100(3):224-5; author reply 225. doi: 10.1093/jnci/djm302. Epub 2008 Jan 29. J Natl Cancer Inst. 2008. PMID: 18230796 No abstract available.
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y. Sunakawa Y, et al. Among authors: kawara k. Cancer Chemother Pharmacol. 2011 Aug;68(2):279-84. doi: 10.1007/s00280-010-1485-8. Epub 2010 Oct 19. Cancer Chemother Pharmacol. 2011. PMID: 20957480
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Yamashita K, Nagashima F, Fujita K, Yamamoto W, Endo H, Miya T, Narabayashi M, Kawara K, Akiyama Y, Ando Y, Ando M, Sasaki Y. Yamashita K, et al. Among authors: kawara k. Jpn J Clin Oncol. 2011 Feb;41(2):204-9. doi: 10.1093/jjco/hyq197. Epub 2010 Oct 21. Jpn J Clin Oncol. 2011. PMID: 20965940 Clinical Trial.
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Sunakawa Y, Fujita K, Ichikawa W, Ishida H, Yamashita K, Araki K, Miwa K, Kawara K, Akiyama Y, Yamamoto W, Nagashima F, Saji S, Sasaki Y. Sunakawa Y, et al. Among authors: kawara k. Oncology. 2012;82(4):242-8. doi: 10.1159/000337225. Epub 2012 Apr 12. Oncology. 2012. PMID: 22508373 Clinical Trial.
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Matsunaga M, Araki K, Tanaka R, Ichikawa W, Miya T, Narabayashi M, Akiyama Y, Kawara K, Ando Y, Sasaki Y. Fujita K, et al. Among authors: kawara k. Biol Pharm Bull. 2008 Nov;31(11):2137-42. doi: 10.1248/bpb.31.2137. Biol Pharm Bull. 2008. PMID: 18981587 Free article. Clinical Trial.
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.
Fujita K, Ando Y, Yamamoto W, Miya T, Endo H, Sunakawa Y, Araki K, Kodama K, Nagashima F, Ichikawa W, Narabayashi M, Akiyama Y, Kawara K, Shiomi M, Ogata H, Iwasa H, Okazaki Y, Hirose T, Sasaki Y. Fujita K, et al. Among authors: kawara k. Cancer Chemother Pharmacol. 2010 Jan;65(2):251-8. doi: 10.1007/s00280-009-1029-2. Cancer Chemother Pharmacol. 2010. PMID: 19466410
Delayed elimination of SN-38 in cancer patients with severe renal failure.
Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, Ishida H, Yamashita K, Mizuno K, Saji S, Ichikawa W, Yamamoto W, Nagashima F, Miya T, Narabayashi M, Ando Y, Hirose T, Sasaki Y. Fujita K, et al. Among authors: kawara k. Drug Metab Dispos. 2011 Feb;39(2):161-4. doi: 10.1124/dmd.110.035451. Epub 2010 Oct 27. Drug Metab Dispos. 2011. PMID: 20980446 Clinical Trial.
25 results